Latest Breaking News On - Mark breidenbach - Page 1 : comparemela.com

BioLineRx Ltd (NASDAQ:BLRX) Q1 2023 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx First Quarter 2023 Financial Results Conference Call.

Kevin campbellPhil serlinEric sappMark breidenbachGenzyme sanofiJoe pantginisJohn laceyElla soraniTami rachmilewitzPhilip serlinJohn vandermostenCorporate communications biolinerxWashington university school of medicineColumbia universityMarket developmentProgram scientific advisory board

Syros Pharmaceuticals, Inc (NASDAQ:SYRS) Q1 2023 Earnings Call Transcript

Operator: Good morning, and welcome to Syros Pharmaceuticals First Quarter 2023 Financial Results Conference Call. [Operator Instructions].

United statesNancy simonianJason butlerJason haasKaren hunadyConley cheeDavid rothPiper sandlerEric olsonChristian stevensMark breidenbachTed tenthoffPhil nadeauCorporate communications at syrosHealth photoSyros pharmaceuticals inc

Agios Pharmaceuticals, Inc (NASDAQ:AGIO) Q1 2023 Earnings Call Transcript

Operator: Good morning, and welcome to Agios First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end.

United statesBrian goffTsveta milanovaMark breidenbachCecilia jonesSarah gheuensGregory renzaTess romeroSalveen richterGreg harrisonDivya raoGoldman sachsAgios pharmaceuticals incHead of researchUniversity of utrechtGulf cooperation council

US FDA approves Seres Therapeutics pill for deadly C difficile infections

US FDA approves Seres Therapeutics pill for deadly C difficile infections
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRaghav mahobeShinjini ganguliAditya samalMark breidenbachMaju samuelJoseph thomeSeres therapeutics incSwitzerland based ferring pharmaceutical

FDA Approves Treatment for Deadly C Difficile Infections

The FDA on Wednesday approved Seres Therapeutics s pill for treating a type of bacterial infection, giving an easier and standardized option to patients who often have to rely on individual donors for fecal transplants.

United statesJoseph thomeRaghav mahobeShinjini ganguliAditya samalMaju samuelMark breidenbachSeres therapeutics incSwitzerland based ferring pharmaceuticalC diff infectionClostridium difficile infectionLostridium difficile associated diseaseC diff associated diseaseFecal transplantationStool transplantEcal bacteriotherapy